NCT04394546进行中（未招募）不适用
WATCHMAN FLX Versus NOAC for Embolic ProtectION in in the Management of Patients With Non-Valvular Atrial Fibrillation
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 3,000
- 试验地点
- 245
- 主要终点
- WATCHMAN FLX is non-inferior (NI) for the occurrence of stroke, cardiovascular death, and systemic embolism
研究概览
简要总结
The primary objective of this study is to determine if left atrial appendage closure (LAAC) with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation.
详细描述
This study is a prospective, randomized, multi-center global investigation. Subjects will be randomized to either the WATCHMAN FLX Left Atrial Appendage Closure Device ("Device Group") or a commercially available non-vitamin K oral anticoagulant ("Control Group").
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject is of legal age to participate in the study per the laws of their respective geography
- •The subject has documented non-valvular atrial fibrillation (i.e., atrial fibrillation in the absence of moderate or greater mitral stenosis or a mechanical heart valve)
- •The subject has a calculated CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack (TIA), vascular disease, age 65 to 74 years, sex category) score of 2 or greater for men and 3 or greater for women
- •The subject is deemed to be suitable for the protocol-defined pharmacologic regimens in both the test and control arms
- •The subject or legal representative is able to understand and willing to provide written informed consent to participate in the trial
- •The subject is able and willing to return for required follow-up visits and examinations
排除标准
- •Subjects who are currently enrolled in another investigational study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments
- •The subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction, for example due to an underlying hypercoagulable state (i.e., even if the device is implanted, the subjects would not be eligible to discontinue OAC due to other medical conditions requiring chronic OAC therapy)
- •The subject is contraindicated or allergic to oral anticoagulation medication and/or aspirin
- •The subject is indicated for chronic P2Y12 platelet inhibitor therapy
- •The subject had or is planning to have any cardiac or non-cardiac intervention or surgical procedure within 30 days prior to or 60 days after implant (including, but not limited to: cardioversion, percutaneous coronary intervention (PCI), cardiac ablation, cataract surgery, etc.)
- •The subject had a prior stroke (of any cause, whether ischemic or hemorrhagic) or transient ischemic attack (TIA) within the 30 days prior to enrollment
- •The subject had a prior major bleeding event per ISTH definition within the 30 days prior to randomization. Lack of resolution of related clinical sequelae or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event
- •The subject has an active bleed
- •The subject has a reversible cause of AF or transient AF
- •The subject is absent of a left atrial appendage (LAA) or the LAA is surgically ligated
- •The subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 30 days prior to enrollment
- •The subject has a history of atrial septal repair or has an atrial septal device (ASD)/patent foramen ovale (PFO) device
- •The subject has an implanted mechanical valve prosthesis in any position
- •The subject has a known contraindication to percutaneous catheterization procedure
- •The subject has a known contraindication to transesophageal echo (TEE)
- •The subject has a cardiac tumor
- •The subject has signs/symptoms of acute or chronic pericarditis.
- •The subject has an active infection
- •There is evidence of tamponade physiology
- •The subject has New York Heart Association Class IV Congestive Heart Failure at the time of enrollment
- •The subject is of childbearing potential and is, or plans to become, pregnant during the time of the study (method of assessment upon study physician's discretion)
- •The subject has a documented life expectancy of less than 3 years
- •Transthoracic Echo Exclusion Criteria:
- •The subject has left ventricular ejection fraction ( LVEF) < 30%
- •The subject has an existing pericardial effusion with a circumferential echo-free space > 5mm
- •The subject has a high-risk PFO with an atrial septal aneurysm excursion > 15mm or length > 15mm
- •The subject has significant mitral valve (MV) stenosis (i.e., MV area <1.5 cm2)
研究组 & 干预措施
Device Group
Experimental
Randomized to WATCHMAN FLX Left Atrial Appendage Closure Device
干预措施: WATCHMAN FLX LAAC Device (Device)
Control Group
Active Comparator
Randomized to non-vitamin K oral anticoagulant (NOAC)
干预措施: Non-Vitamin K Oral Anticoagulant (Drug)
结局指标
主要结局
WATCHMAN FLX is non-inferior (NI) for the occurrence of stroke, cardiovascular death, and systemic embolism
时间窗: 36-months
non-inferiority
WATCHMAN FLX is superior for non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding)
时间窗: 36-months
superiority
WATCHMAN FLX is non-inferior (NI) for the occurrence of ischemic stroke and systemic embolism
时间窗: 60-months
non-inferiority
次要结局
- The occurrence of ISTH major bleeding(60-months)
- The occurrence of cardiovascular (CV) death, all stroke, systemic embolism (SE), and non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding)(60-months)
- The occurrence of ISTH major bleeding(60-months)
- The occurrence of cardiovascular (CV) death, all stroke, systemic embolism (SE), and non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding)(36-months)
- The occurrence of ISTH Major Bleeding(36-months)
研究者
研究点 (245)
Loading locations...
相似试验
进行中（未招募）
不适用
SIMPLAAFY Clinical TrialBleedingAtrial FibrillationStrokeNCT06521463Boston Scientific Corporation1,857
已完成
不适用
Watchman FLX Left Atrial Appendage Closure Device Post Approval Study ( Europe Only)Non-valvular Atrial FibrillationNCT02654470Boston Scientific Corporation300
进行中（未招募）
不适用
Comparison of Amplatzer Amulet and Watchman Device in Patients Undergoing Left Atrial Appendage Closure. (SWISS-APERO)Left Atrial Appendage ClosureNCT03399851Insel Gruppe AG, University Hospital Bern200
已完成
不适用
Comparison of Anticoagulation With Left Atrial Appendage Closure After AF AblationAtrial FibrillationNCT03795298Boston Scientific Corporation1,600
已完成
不适用
Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)Atrial FibrillationNCT01196897Boston Scientific Corporation69